Abstract: The disclosure relates to barcoded polymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, associated with polynucleotide barcodes, for therapeutic delivery, and for high throughput in vivo screening of drug delivery nanoparticles.

Abstract: The disclosure relates to barcoded polymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, associated with polynucleotide barcodes, for therapeutic delivery, and for high throughput in vivo screening of drug delivery nanoparticles.

Abstract: The invention relates to barcoded nucleic acid nanostructure delivery compositions for in vivo screening for subsequent use in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to nucleic acid nanostructure delivery compositions, such as DNA origami structures, associated with barcodes for high throughput in vivo screening of the nucleic acid nanostructure delivery compositions for subsequent use in drug delivery, and methods therefor.

Abstract: Technologies for identifying genetic engineering proteins, organisms, and context signatures include a computing device that may be in communication with multiple client devices. The technologies include receiving a query sequence for a biological specimen, determining an alignment of the query sequence for regions of interest, and determining whether a match exists upstream or downstream from the region of interest in a predetermined database of genetic engineering context signatures. The search range may be predetermined based on each context signature. The technologies further include determining an alignment of the query sequence against a predetermined database of sequences indicative of genetic engineering, and determining whether a similarity score of the alignment exceeds a predetermined threshold. The database may include a genetic engineering protein database or a genetic engineering organism database. Other embodiments are described and claimed.

Abstract: The disclosure relates to barcoded polymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, associated with polynucleotide barcodes, for therapeutic delivery, and for high throughput in vivo screening of drug delivery nanoparticles.